Health
We’re making a flurry of moves: trimming 2 stocks and buying 2 others that have lagged
We’re making four trades Monday morning. Shortly after the opening bell, we will be selling 100 shares of Danaher at roughly $274.13. Following the trade, Jim Cramer’s Charitable Trust will own 475 shares of Danaher, decreasing its weighting in the portfolio to 4% from 4.84%. In addition, we will be selling 20 shares of Salesforce at […]
Read More
FDA approves new blood test to screen for colon cancer
The Food and Drug Administration on Monday approved Guardant Health’s blood test, called Shield, to screen for colon cancer. The test isn’t meant to replace colonoscopies, but is generating enthusiasm among doctors who say it has the potential to boost the dismal rate of screenings for the second-highest cause of cancer death in the United States. Shield […]
Read More
These drugmakers are catching up to Eli Lilly and Novo Nordisk in weight loss treatments
The lucrative market for weight loss drugs won’t stay a duopoly forever. With billions at stake, that’s pretty much been a guarantee facing the current market leaders, Eli Lilly and Novo Nordisk , from the start. But the reality of the coming competition has grown more tangible after recent announcements from rival drugmakers Roche and […]
Read More
Dexcom shares plunge more than 40%, head for worst day on record
Dexcom shares sank more than 40% on Friday and headed for their worst day ever after the diabetes management company reported disappointing revenue for the second quarter and offered weak guidance. The stock fell $45.38 to $62.47 as of early afternoon, wiping out about $18 billion in market cap. Prior to Friday, the biggest drop […]
Read More
An ugly earnings report from a competitor is good news for Abbott Labs
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Friday’s key moments. Stocks jumped Friday as Wall Street tried to end a turbulent week on a jubilant note. The Dow Jones Industrial Average added more more than 600 points, or 1.6%. The […]
Read More
European drug regulator rejects Alzheimer’s treatment Leqembi from Biogen, Eisai
European drug regulators on Friday rejected the Alzheimer’s treatment Leqembi from Biogen and Eisai, creating another hurdle for the companies as they scramble to boost uptake of the therapy in the U.S. The European Commission, the EU’s executive body, has a final say in Leqembi’s approval. But it almost always follows the drug regulator’s recommendations. […]
Read More
Beyond Novo and Eli Lilly: Watch these biotech and weight loss drug names, fund manager says
Weight loss drugs have drawn investor interest and shaken up other sectors in the past year or so. Novo Nordisk and Eli Lilly were two early winners of this trend, as their drugs dominate the weight loss drug market. Yuri Khodjamirian, fund manager at Tema ETFs, said both companies are a “very powerful duopoly.” “But […]
Read More
Viking Therapeutics stock jumps 16% after drugmaker moves weight loss injection to late-stage trial
Weight loss drug concept. Cr | Istock | Getty Images Shares of Viking Therapeutics jumped 16% in premarket trading Thursday after the biotech company a day earlier announced plans to advance its experimental weight loss injection into a late-stage trial earlier than expected. It brings the San Diego-based company one step closer to joining the […]
Read More
India is on alert after a fresh outbreak of the deadly Nipah virus. Here’s what you need to know
Fruit bats seen hanging on tree branches in daylight. Bats are believed to be one of the carriers of Nipah virus, a zoonotic disease that spreads from animals to humans. Eyepix Group | Future Publishing | Getty Images Health authorities in the southern Indian state of Kerala are on high alert following the latest flare-up of the […]
Read More
Pfizer’s gene therapy for rare genetic bleeding disorder succeeds in late-stage trial
Kena Betancur | Corbis News | Getty Images Pfizer on Wednesday said its experimental gene therapy for a rare genetic blood-clotting disorder succeeded in a large late-stage trial, paving the way for a potential approval. The treatment for hemophilia A could become the company’s second gene therapy to enter the U.S. market after Beqvez, which […]
Read More